MedTrace Logo

Hematotoxicity in Maintenance Therapy of Children With Acute Lymphoblastic Leukemia

NCT03255668 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 106

Last updated 2018-11-20

No results posted yet for this study

Summary

Subjects who are recruited in this study are LLA patient, who are treated for routine control to Cipto Mangunkusumo Hospital, who meet the inclusion criteria and do not meet the exclusion criteria.

Conditions

  • Mercaptopurine Adverse Reaction
  • Leukemia, Lymphoblastic

Sponsors & Collaborators

  • Indonesia University

    lead OTHER

Principal Investigators

  • Rianto Setiabudy, Professor · Department of Pharmacology and therapeutic, FMUI

  • Djajadiman Gatot, Professor · Department of Pediatric

Eligibility

Min Age
1 Year
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-25
Primary Completion
2018-10-15
Completion
2018-11-01

Countries

  • Indonesia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03255668 on ClinicalTrials.gov